---
title: "Esophageal Cancer Treatment"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    css: "lci_styles.css"
    theme: [simple, lci.scss]
    echo: false
  #nanotes_pdf: default
  pdf:
    includes:
      in-header: "preamble.tex"
  #pptx: 
    #reference-doc: talks.pptx
editor: visual
bibliography: zotero.bib
---

## Esophageal Cancer Treatment Categories

| Category             |   Stage    | Treatment                  |
|----------------------|:----------:|:---------------------------|
| [Superficial Tumors] |    T1a     | Endoscopic Therapy         |
| [Localized Tumors]   |   T1b T2   | Surgery                    |
| [Locally-advanced]   | T3 or N^+^ | Chemo$\pm$ RT → Surgery    |
| [Metastatic]         |     M1     | Chemotherapy +/- Radiation |


## Superficial Tumors

Workup of nodular Barretts esophagus:

-   Endoscopic Ultrasound
-   Endoscopic Mucosal Resection
    -   Diagnostic (T staging)
    -   May be therapeutic for T1a tumors

## Endoscopic Musocal Resection

:::: {.columns align="center"}
::: {.column width="50%"}
![](images/t1a_nolabel){fig-align="center"}
:::

::: {.column width="50%"}


![](images/t1a_lift2.png){fig-align="center"}
:::
::::


## Endoscopic Musocal Resection

:::: {.columns align="center"}
::: {.column width="50%"}
![](images/tumor_EMR_snare.png){fig-align="center"}
:::

::: {.column width="50%"}
![](images/t1a_postemr.png){fig-align="center"}
:::
::::



## EMR Favorable Features

:::: {.columns align="center"}
::: {.column width="50%"}
- Clear Margins
- Size <2cm
- No Lymphovascular
- Well-differentiated

- Overall good prognosis
- EGD in 6 months for surveillance
:::

::: {.column width="50%"}
![](images/emr_favorable_zoom.png){fig-align="center"}
:::
::::


## EMR Unfavorable Features

:::: {.columns align="center"}
::: {.column width="50%"}
- Involved Margins
- Size >2cm
- Lymphovascular invasion
- Poorly differentiated

- High risk for recurrence
- EGD in 3 months for surveillance
:::

::: {.column width="50%"}
![](images/EMR_unfavorable_zoom.png){fig-align="center"}
:::
::::

## EMR Deep Positive Margin


:::: {.columns align="center"}
::: {.column width="50%"}
Patients with positive deep margin on EMR are likely understaged.

Strong consideration for surgery due to risk of lymph node metastasis
:::

::: {.column width="50%"}
![](images/EMR_Positive_Deep.png){fig-align="center"}
:::
::::


## Localized Tumors

Patients staged as uT2 N0 are candidates for primary surgery. *However:*

-   EUS has a 25% rate of understaging uT2 N0 tumors
-   Understaged patients who undergo primary surgery need chemo or chemoRT postop

## Asymptomatic Tumors (minimal dysphagia)

-   EUS to distinguish T2 from T3 tumors
-   If uT2 N0 $\rightarrow$ CT chest/abdomen/pelvis $\rightarrow$ Esophagectomy
-   If uT3 or N1 $\rightarrow$ PET $\rightarrow$ neoadjuvant therapy

Patients with dysphagia almost always are T3 tumors (and don't need EUS)

## Symptomatic Tumors (dysphagia)

Patients with dysphagia to solids or weight loss or tumor length \>3cm are unlikely to have T1-2 tumors and can be initially evaluated with [PET Scan]

-   Disease confined to the esophagus and regional nodes $\rightarrow$ [Locally-advanced]
-   Metastatic disease $\rightarrow$ [Metastatic]
-   N3 $\rightarrow$ induction chemotherapy followed by chemoradiation and surgical evaluation.

## EUS in Patients with Dysphagia

Memorial Sloan Kettering patients with esophageal cancer:

-   61 with dysphagia, 54 (89%) were found on EUS to have uT3-4 tumors.
-   53 without dysphagia, 25 (47%) were uT1-2 $\rightarrow$ candidates for primary surgery.

EUS can be omitted for patients with dysphagia, but is useful in patients *without* dysphagia.

::: aside
[@ripley226]
:::

## Squamous Cell Carcinoma



:::: {.columns align="center"}
::: {.column width="50%"}
CROSS Regimen

Weekly Carboplatin + Paclitaxel

5040 cGy radiation in 28 fractions
:::

::: {.column width="50%"}
![Surgery vs ChemoRT$\rightarrow$ Surgery by Histology](images/shapiro_1090_fig2b.png){fig-align="center"}
:::
::::

## Restaging after ChemoRT - SCCa

PET at 6 weeks

EGD at 6 weeks

CROSS trial had 49% pCR for squamous cell carcinoma

$\doublerightarrow$ Majority of patients never need surgery

## Restaging after ChemoRT - SCCa

![Restaging after ChemoRT](images/CRT_surgical_candidate.jpg){fig-align="left"}
## Immediate Surgery Strategy

![ChemoRT $\rightarrow\ Surgery](images/CRT_immediate_surgery.jpg){fig-align="left"}

Difficult to justify immediate surgery for squamous cell carcinoma with 50% pCR rate

## Restaging after ChemoRT - SCCa

![Restaging after ChemoRT](images/CRT_restaging_EGD.jpg){fig-align="left"}
## Restaging after ChemoRT - SCCa

![ChemoRT $\rightarrow$ EGD Positive](images/CRT_restaging_EGD_pos.jpg){fig-align="left"}
## Restaging after ChemoRT - SCCa

![ChemoRT $\rightarrow$ EGD Negative](images/CRT_restaging_EGD_neg.jpg){fig-align="left"}

## Active Surveillance for SCCa Esophagus

![ChemoRT $\rightarrow$ EGD Negative](images/CRT_AS_outcome_SCCA.jpg){fig-align="left"}
## SANO trial

![SANO Cinital Trial Schema](images/CRT_AS_outcome_SCCA.jpg){fig-align="left"}

## SANO Surveillance Schema

![SANO Cinital Trial Schema](images/SANO_schema_notext.jpg){fig-align="left"}
## SANO Surveillance Schema

![SANO Cinital Trial Schema](images/SANO_schema_text.jpg){fig-align="left"}

## Adenocarcinoma

CROSS data would suggest benefit from preoperative ChemoRT is less dramativ with adenocarcinoma

## CROSS Treatment Failures

![Relapse-free Survival](images/shapiro_1090_fig2b.png){fig-align="left"}

##
![ChemoRT $\rightarrow$ EGD](images/eyck_modified.png){fig-align="left"}

::: aside
[@shapiro1090]
:::




## ESOPEC: FLOT Perioperative Chemo vs CROSS ChemoRT


![ChemoRT $\rightarrow$ EGD](images/ESOPEC_survival_modified.png){fig-align="left"}
::: aside
[@hoeppner323]
:::

## Locally Advanced Adenocarcinoma

::::: columns
::: {.column width="50%"}
**Chemo + Radiation**

-   Better tolerated
-   Candidates for adjuvant immunotx
-   Port usually placed
-   More dysphagia (last 2 weeks of Tx)
-   Dysphagia resolved 2-3 weeks later
-   More likely to need feeding tube
:::

::: {.column width="50%"}
**Chemotherapy**

-   More effective
-   More toxicity (neutropenia)
-   Port always required
-   Eating slowly improves
-   Less likely to need feeding tube
:::
:::::

## Esophagectomy at CMC

Minimally-invasive approach
500+ cases since 2007
Laparoscopic/VATS $\rightarrow$ Robotic
8% anastomotic leak
5.5% 90-day mortality

## Frailty Assessment

![Grip Strength $\rightarrow$ CT Body Composition](images/CMC_slides/HGS_CT.png){fig-align="left"}


## Body Composition and Age Predict Operative Mortality

![90-day mortality =$f(age + body composition)$](images/CMC_slides/BC_90Day_XY.png){fig-align="left"}


## Body Composition and Age Predict Operative Mortality

![90-day mortality =$f(age + body composition)$](images/CMC_slides/BC_90Day_Matrix.png){fig-align="left"}



## Can Body Composition Predict Benefit of Surgery

316 esophageal cancer treated with chemo + radiation​

- Surgery in 254
- No surgery in 62

Cohort stratified by age and body composition
- Low Risk (top 75%)
- High Risk (bottom 25%)

## Survival Benefit of Surgery - Normal Muscle

![90-day mortality =$f(age + body composition)$](images/CMC_slides/LowRisk_label.png){fig-align="left"}

## Survival Benefit of Surgery - Low Muscle

![90-day mortality =$f(age + body composition)$](images/CMC_slides/HighRisk_label.png){fig-align="left"}

##  {background-color="#b22222"}

## Locally Advanced

Treatment depends upon histology:

[Squamous Cell Carcinoma]

[Adenocarcinoma]



## Metastatic

FOLFOX is first-line systemic therapy for metastatic GI cancers

-   Dose-limiting toxicity is frequently peripheral neuropathy


## References
